Pancreatic fistula medical therapy: Difference between revisions
Created page with "__NOTOC__ {{Pancreatic_fistula}} {{CMG}} ==Overview== ==Medical Therapy== The production of pancreatic enzymes is suppressed by restricting the patient's oral intake of food..." |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. Medical therapy is tailored towards the suppression of pancreatic enzymes by restricting the patient's oral intake of food in conjunction with the use of long-acting [[somatostatin]] analogues such as octreotide. The patient's nutrition is maintained by [[total parenteral nutrition]]. | |||
This treatment is continued for 2-3 weeks, and the patient is observed for improvement. | |||
==Medical Therapy== | ==Medical Therapy== | ||
Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. Medical therapy is tailored towards the suppression of pancreatic enzymes by restricting the patient's oral intake of food in conjunction with the use of long-acting [[somatostatin]] analogues such as octreotide.<ref>{{cite journal | author=Takeo C, Myojo S | title=Marked effect of octreotide acetate in a case of pancreatic pleural effusion | journal=Curr Med Res Opin | year=2000 | pages=171-7 | volume=16 | issue=3 | id=PMID 11191006}}</ref> Octreotide is used commonly to control pancreatic secretion, however, no significant benefit is observed with its use in patients with already established pancreatic fistula.<ref name="pmid32809706">{{cite journal| author=| title=StatPearls | journal= | year= 2021 | volume= | issue= | pages= | pmid=32809706 | doi= | pmc= | url= }} </ref> The patient's nutrition is maintained by [[total parenteral nutrition]]. | |||
This treatment is continued for 2-3 weeks, and the patient is observed for improvement. | This treatment is continued for 2-3 weeks, and the patient is observed for improvement.<ref name="pmid29588609">{{cite journal| author=Nahm CB, Connor SJ, Samra JS, Mittal A| title=Postoperative pancreatic fistula: a review of traditional and emerging concepts. | journal=Clin Exp Gastroenterol | year= 2018 | volume= 11 | issue= | pages= 105-118 | pmid=29588609 | doi=10.2147/CEG.S120217 | pmc=5858541 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29588609 }} </ref> | ||
==References== | ==References== | ||
Revision as of 18:43, 5 April 2021
|
Pancreatic fistula Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pancreatic fistula medical therapy On the Web |
|
American Roentgen Ray Society Images of Pancreatic fistula medical therapy |
|
Risk calculators and risk factors for Pancreatic fistula medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. Medical therapy is tailored towards the suppression of pancreatic enzymes by restricting the patient's oral intake of food in conjunction with the use of long-acting somatostatin analogues such as octreotide. The patient's nutrition is maintained by total parenteral nutrition. This treatment is continued for 2-3 weeks, and the patient is observed for improvement.
Medical Therapy
Treatment of pancreatic fistula includes early recognition of the problem which is the key to careful management in order to prevent the consequent complications. Medical therapy is tailored towards the suppression of pancreatic enzymes by restricting the patient's oral intake of food in conjunction with the use of long-acting somatostatin analogues such as octreotide.[1] Octreotide is used commonly to control pancreatic secretion, however, no significant benefit is observed with its use in patients with already established pancreatic fistula.[2] The patient's nutrition is maintained by total parenteral nutrition. This treatment is continued for 2-3 weeks, and the patient is observed for improvement.[3]
References
- ↑ Takeo C, Myojo S (2000). "Marked effect of octreotide acetate in a case of pancreatic pleural effusion". Curr Med Res Opin. 16 (3): 171–7. PMID 11191006.
- ↑ "StatPearls". 2021. PMID 32809706 Check
|pmid=value (help). - ↑ Nahm CB, Connor SJ, Samra JS, Mittal A (2018). "Postoperative pancreatic fistula: a review of traditional and emerging concepts". Clin Exp Gastroenterol. 11: 105–118. doi:10.2147/CEG.S120217. PMC 5858541. PMID 29588609.